Spots Global Cancer Trial Database for Dual Vaccine Trial in Myeloproliferative Neoplasms
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Dual Vaccine Trial in Myeloproliferative Neoplasms
Official Title: Dual Vaccine Trial in Myeloproliferative Neoplasms
Study ID: NCT04051307
Study Description
Brief Summary: A phase I-II study in patients with mutated MPN by vaccinating with PD-L1 and Aginase1 peptides with Montanide ISA-51 as adjuvant, to monitor the immunological response to vaccination and subsequently safety, toxicity and clinical effect.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Herlev Hospital, Herlev, Capital Region, Denmark
National Center for Cancer Immune Therapy (CCIT-DK), Herlev, , Denmark
Contact Details
Name: Jacob H Grauslund, MD
Affiliation: CENTER FOR CANCER IMMUNE THERAPY, CCIT-DK
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
